Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous ... - PR-USA.net (press release)
PR-USA.net (press release) Vascugel has demonstrated clinical proof of concept in two Phase 2 clinical trials involving patients with ESRD who require a permanent arteriovenous (AV)